SALT LAKE CITY--(BUSINESS WIRE)--July 9, 1998--IOMED(R) Inc. (AMEX:IOX) Thursday announced the release of its newest generation of iontophoretic dose controller, the Numby(R) 900.
This new controller with simple push button operation delivers fast and effective local dermal anesthesia when used in conjunction with IOMED's Numby Stuff(R) electrodes and IONTOCAINE(R)(a), IOMED's anesthetic medication.
The Numby 900 is a component of IOMED's iontophoretic drug delivery system, which is the needle-free way of delivering certain types of medications into and through the skin using a mild, low-level electrical current from a small battery-operated, dose controlling unit.
The compact, portable design of Numby 900 makes delivering local dermal anesthesia simple for clinicians. The Numby 900 offers:
Simple, effective push-button controls
Pre-programmed dose with variable current options for fast, easy
Integrated state-of-the-art electronics for maximum patient
comfort, safe drug delivery and proven IOMED reliability
The device performs internal checks before and during each treatment. Audible and visual alarms are activated if any problems are detected or if the battery needs replacement. Treatments may also be stopped manually at any time.
The Numby 900 is used in combination with IOMED's pediatric pain management product, Numby Stuff, which is used to numb an area of the skin prior to painful local procedures. Numby Stuff delivers anesthesia in as little as 10 minutes and numbs the skin and underlying tissue up to a depth of 10 millimeters.
"The Numby 900 is easy to use, allowing physicians or nurses to operate the dose controller by pushing a single button," said Ned M. Weinshenker, Ph.D., IOMED's president and chief executive officer. "In addition, the compact size and portability of the device is ideal to treat pediatric patients or to allow for mobility while patients are receiving treatments."
For additional information regarding the Numby 900 or purchase inquiries, please contact IOMED Customer Service at 800/621-3347.
(a) Note to Editors: IONTOCAINE (lidocaine HCI 2% with epinephrine 1:100,000 Topical Solution) complete prescribing information available upon request.
IOMED Inc. (www.iomed.com) is a leader in the research, development and manufacture of iontophoretic drug delivery systems that are marketed to health care providers worldwide. Advanced research for local and systemic delivery of ionic pharmaceutical compounds to treat various medical conditions is conducted by its wholly owned subsidiary, Dermion Inc. IOMED is based in Salt Lake City.
The statements contained in this release that are not purely historical are forward-looking statements, as defined in section 21E of the Securities and Exchange Act of 1934, and include IOMED's beliefs, expectations, or intentions, regarding its future operations and financial condition.
All forward-looking statements included in this release are made as of the date hereof and are based upon information available to IOMED as of such date. IOMED assumes no obligation to update any forward-looking statement.
It is important to note that actual outcomes could differ materially from those in such forward-looking statements. Readers should also refer to the risk and other disclosures set forth in IOMED's filings with the Securities and Exchange Commission on Forms S-1 and 10-Q.
CONTACT: IOMED Inc., Salt Lake City
Pat Daimler, 801/975-1191
PPCH Public Relations
Stephanie Miller, 801/487-4800
COPYRIGHT 1998 Business Wire
COPYRIGHT 2000 Gale Group